Search Results - "Bayo, Juan L."

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy by Gámez-Pozo, Angelo, Pérez Carrión, Ramón M, Manso, Luis, Crespo, Carmen, Mendiola, Cesar, López-Vacas, Rocío, Berges-Soria, Julia, López, Isabel Álvarez, Margeli, Mireia, Calero, Juan L Bayo, Farre, Xavier González, Santaballa, Ana, Ciruelos, Eva M, Afonso, Ruth, Lao, Juan, Catalán, Gustavo, Gallego, José V Álvarez, López, José Miramón, Bofill, Francisco J Salvador, Borrego, Manuel Ruiz, Espinosa, Enrique, Vara, Juan A Fresno, Zamora, Pilar

“…Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular…”
Get full text

Efficacy and safety of second-line immunotherapy in patients with advanced non-small cell lung cancer by Sánchez Escudero, Laura, Cobelas Cartagena, Stephanie S., Sánchez Esperilla, María, Bayo, Juan L.

“…e20571 Background: Patients (Pts) with advanced non-small cell lung cancer (NSCLC) face limited treatment options. Immunotherapy (IO) has revolutionized the…”
Get full text

Is HER2 expression related to CDKi efficacy in HER2-negative luminal metastatic breast cancer? by Garcés, María Yeray Rodríguez, Fernández Madrigal, Laura, Morales Pancorbo, David, Bayo, Juan L.

“…e13073 Background: Cyclin kinase inhibitors (CDKi) are the standard of care in the first line of luminal (Lum) metastatic breast cancer (MBC). HER2…”
Get full text

Combined role of the neutrophil/lymphocyte ratio and Neo-Bioscore in neoadjuvant therapy in HER2-positive early breast cancer by Sánchez Escudero, Laura, Cobelas Cartagena, Stephanie S, Morales Pancorbo, David, Bayo, Juan L.

“…e12613 Background: High neutrophil/lymphocyte ratio (NLR) is considered a poor prognostic factor in triple negative breast cancer but its role in HER2-positive…”
Get full text

Neoadjuvant therapy with concurrent anthracyclines and taxanes in Her2-negative breast cancer (HNBC): TAC legacy by García Samblás, Victoria, David, Morales Pancorbo, Aragon Manrique, Isabel, Bayo, Juan L.

“…e12629 Background: Adyuvant therapy with Concurrent docetaxel-adriamycin-cyclophosphamide (TAC) increases overall survival in positive node breast cancer…”
Get full text

Descriptive study of the therapeutic aggressiveness in oncology patients in the hospital area of Huelva by Amor Urbano, María, Sánchez Escudero, Laura, Palomo Rodríguez, Rocío, Inoriza, Angel, Camacho Pizarro, Tomás, Bayo, Juan L.

“…Abstract only e18645 Background: The therapeutic aggressiveness (TA) criteria or Earle criteria (EC) (Table) explore indicators that reflect the quality of…”
Get full text

Assessment of Spanish hospitals involved in the Quality Oncology Practice Initiative program by Garcia-Foncillas, Jesus, Lopez, Rafael, Camps, Carlos, Guillem, Vicente, Alonso, Jose Luis, Carrato, Alfredo, Martín, Nicole, Paz-Ares, Luis G., Provencio, Mariano, Esteban, Emilio, Ayala, Francisco, Pérez-Segura, Pedro, Narbona, Javier, Bayo, Juan L., Bessa, Maria, Gratal, Paula

“…305 Background: Measuring and tracking quality of care is highly relevant in today’s healthcare. The Quality Oncology Practice Initiative (QOPI) program is a…”
Get full text

Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC) by Salvador, Javier, Ruiz Borrego, Manuel, Valero, Maria, Bayo, Juan L., De La Cruz-Merino, Luis, Carabantes, FRancisco, Rodriguez de la Borbolla, Maria

“…Abstract only e11577 Background: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of…”
Get full text

Prognostic analysis according to the expression of hormone receptors in HER2-positive breast cancer by Gallego Jimenez, Inmaculada, Morales Pancorbo, David, Fuentes Pradera, Jose, Salvador, Javier, Bayo, Juan L., Bernabé, Reyes, Rodriguez de la Borbolla, Maria, Fernandez Parra, Eva, Lopez Ladron, Amelia

“…Abstract only e11075 Background: Overexpression HER 2 + + + is a distinct group within the breast cancer with different treatments in both the adjuvant and…”
Get full text

Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625 by Blancas, Isabel, Ruiz-Borrego, Manuel, Salvador Bofill, Javier, Conde, Veronica, Carabantes, Francisco, Bayo, Juan L., Jaen, Ana, Perez Ruiz, Elisabeth, Santiago, María del Mar, Baena, Jose Manuel, Villareal, Vicente, Martinez Guisado, Antonia, de la Cruz Merino, Luis, Rodriguez, Pedro, Reyes, Evelyn, Cajal, Rosana, Delgado, Mayte, Gonzalez Flores, Encarnacion, Inoriza, Angel, Sanchez Rovira, Pedro

“…Abstract only e11583 Background: The CONFIRM study showed greater efficacy of F500 as compared to F250.Based on these results a dosage change was authorized in…”
Get full text

The Long-HER study: Clinical and molecular analysis of advanced HER2+ breast cancer treated with trastuzumab and associated to long-term survival by Espinosa, Enrique, Gámez-Pozo, Angelo, Perez Carrion, Ramon Maria, Manso, Luis, Crespo, Carmen, Mendiola, Cesar, Alvarez, Isabel, Margeli, Mireia, Bayo, Juan L., Gonzalez, Xavier, Santaballa, Ana, Ciruelos, Eva, Cabrera, Miguel Angel, Anton, Antonio, Catalan, Gustavo, Álvarez Gallego, José Valero, Miramon, Jose, Lopez Vacas, Rocio, Zamora, Pilar

“…Abstract only 608 Background: Some patients with advanced HER2+ breast cancer survive in the long-term after receiving trastuzumab-based therapy. Long-HER…”
Get full text

Study of the usefulness of angiotensin type 1 receptor (AGTR1) as a possible response predictor in patients with metastatic breast cancer (mBC) subjected to chemotherapy and treatment with bevacizumab (AVALUZ Study) by De la Haba- Rodriguez, Juan, Salvador Bofill, Javier, Codes, Manuel, Ciruelos, Eva M., Jaen, Ana, Galan, Antonio, Gil, Miquel, Serrano, M. Jose, Baena, Jose Manuel, Villanueva Silva, Maria Jose, Gonzalez, Encarnacion, Murias, Adolfo, Miguel, Ana, Garcia, Helena, Bayo, Juan L., Sánchez-Rovira, Pedro

“…Abstract only 10608 Background: Angiotensin type 1 receptor (AGTR1) is a membrane receptor implicated in the regulation of arterial pressure. It has also been…”
Get full text

AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: OS analysis by Salvador, Javier, Ciruelos, Eva M., Codes, Manuel, Jaen, Ana, Gil, Miquel, Galan, Antonio, Murias, Adolfo, Jara-Sanchez, Carlos, De la Haba- Rodriguez, Juan, Baena, Jose Manuel, Villanueva Silva, Maria Jose, Bayo, Juan L., Blancas, Isabel, Gonzalez, Encarnacion, Perez, Diego, Mel, Jose Ramón, Manso, Luis

“…Abstract only e11535 Background: The combination of bevacizumab (B) with taxanes, capecitabine or anthracyclines has shown increased PFS in pts with mBC. The…”
Get full text

Value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab (B) in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy (AVALUZ trial) by Codes, Manuel, Manso, Luis, Ciruelos, Eva M., De la Haba- Rodriguez, Juan, Galan, Antonio, Baena, Jose Manuel, Jaen, Ana, Gil, Miquel, Murias, Adolfo, Blancas, Isabel, Gonzalez, Encarnacion, Perez, Diego, Bayo, Juan L., Mel, Jose Ramón, Garcia-Martinez, Elena, Cubedo, Ricardo, Salvador, Javier

“…Abstract only e21088 Background: CTCs in peripheral blood are an ideal source for the detection of tumor dissemination. Their prognosis significance has been…”
Get full text